Molecular detection of circulating tumor cells and cell-free nucleic acids
Molecular Pathology in Clinical Practice:Second Edition, Page: 515-523
2016
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Book Chapter Description
One of the key roles performed by pathologists is determination of the presence or absence of tumor in clinical samples. This is the basis for most approaches to staging, monitoring response to treatment, and detecting relapse of neoplasia and, as such, is a critical step in determining the course of patient management. Pathologists have utilized a variety of methods, continually seeking to improve assay performance and thus patient outcome. The literature reflects this quest, including reports assessing the increased sensitivity afforded by immunohistochemistry (IHC), flow cytometry, and, more recently, molecular approaches for the detection of tumor cells and nucleic acids in blood and bone marrow samples. The goal is, of course, the more accurate detection of disease spread and, ultimately, better patient care.This chapter addresses some of the recent work in tumor detection, focusing on molecular and, to some degree, immunofluorescent approaches for the detection of circulating tumor cells and free nucleic acids in clinical samples. A synopsis of the hundreds of articles published to date is beyond the scope of this chapter; instead, more general issues and findings are addressed, along with presentation of selected work. Several reviews are available for more detailed reading (Alix-Panabières and Pantel, Clin Chem 59:110-118, 2013; Pinzani et al., Methods 50:302-307, 2010; Pratt et al. Chem Eng Sci 66:1508-1522, 2011; Schwarzenbach et al., Nat Rev Clin Oncol 11:145-156, 2014).
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85027490002&origin=inward; http://dx.doi.org/10.1007/978-3-319-19674-9_39; https://link.springer.com/10.1007/978-3-319-19674-9_39; https://dx.doi.org/10.1007/978-3-319-19674-9_39; https://link.springer.com/chapter/10.1007/978-3-319-19674-9_39
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know